Tag Archives: Policy

Plans for alien contact found wanting

Enormous satellite dishes make up the search party for extraterrestrial life, but in the event of success, should a welcome party follow? Astronomers and biologists involved in the search for life on other planets are worried about a lack of regulatory and ethical policies to guide them.

“No government has plans” for what to do in the event of the discovery of intelligent extraterrestrial life, says astrophysicist Martin Dominik of the University of St Andrews, UK, who organized a conference at the Royal Society in London that began today

Read the entire news story at Nature News [html] or here [pdf]

Spanish awards rekindle old rivalries

nature_cover_091203An ambitious effort to develop Spanish universities into campuses that are among Europe’s best has stoked some long-standing regional rivalries.

On 26 November, the government announced which universities would benefit from the inaugural round of an annual programme called the Campus of International Excellence, administered jointly by the Ministry of Science and Innovation and the Ministry of Education. The €150-million (US$226-million) scheme is designed to steer resources, in the form of government seed money and loans, to the strategic infrastructure projects with the most potential to aid teaching and research.

Read the entire news story on Nature.com [html] or here [pdf]

Sluggish generics entry prompts calls for European patent reform

Nature Medicine November 2009 coverThis past July, the European Commission released  estimates that if generic drugs were to enter markets immediately after patents expire—instead of the present average of seven months later—EU patients and national health services might save €3 billion ($4.5 billion) annually. But regulators acknowledge that costly and time-consuming patent disputes, and possible anticompetitive practices in the pharmaceutical industry, mean that such savings remain elusive. Continue reading Sluggish generics entry prompts calls for European patent reform

(Stem cell) banking crisis

stemcellbankingLike most stem cell biologists, Helen Mardon obtained her first cell lines from someone she knew. Later, when she needed more material, she chose to pay for a line from a commercial dealer. Eventually, the Oxford Stem Cell Institute co-director derived her own in-house human embryonic stem cell core from embryos donated by in vitro fertilization patients.

Mardon could have gotten human embryonic stem cell (hESC) lines for the cost of delivery from the UK Stem Cell Bank (SCB), one of a handful of stem cells banks worldwide (See A bank in England for stem cells). Supported by government funds, the bank stores, distributes and provides ethical oversight of hESC lines in Britain free of charge to academic and commercial researchers. The samples they distribute are top notch: a half-dozen bench researchers screen their stocks to ensure banked lines are free from viral infections or mycoplasma contamination, and routine checks are also completed before lines are shipped. But for now, Mardon says, “going through the bank just adds a huge layer of paperwork and bureaucracy”.

Continue reading (Stem cell) banking crisis